HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE…
European Commission approves RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line…
Continuous Biomarker Monitoring Pioneer Proton Intelligence Inc Announces a $6.95 Million Seed Raise to Initiate Human Trials for Potassium Monitoring in Patients With Kidney Disease
VANCOUVER, British Columbia & MELBOURNE, Australia--(BUSINESS WIRE)--Proton Intelligence Inc., developing the first-ever…
Research by City of Hope and Other Scientists May Help Patients Overcome Resistance to Chimeric Antigen Receptor (CAR) T Cell Therapy
Research on New System Published in Nature Biomedical Engineering Platform Engineers T…
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
Tuesday, December 17, 2024 at 8:00 am EST December 16, 2024 18:15…
The Esthetic Clinics Attracts 15% Global Patients to India, Amid Cosmetic Surgery Medical Tourism Boom: MedTalks News
MUMBAI, India, Dec. 13, 2024 /PRNewswire/ -- MedTalks News features The Esthetic Clinics®…
5th Anniversary: ICPO Foundation is empowering a new era of cancer treatment with Radiotheranostics for patients worldwide
Launching the "ICPO Academy for Theranostics" and creating its global network of…
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz
** IND submitted to the FDA showing significantly improved patient condition when…
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
December 08, 2024 12:00 ET | Source: Affimed N.V. The combination of…
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 08, 2024 12:00 ET | Source: Cogent Biosciences, Inc. 52% ORR…